{"id":{"repo_id":"cape-town","oai_identifier":"oai:open.uct.ac.za:11427/3099"},"canonical_url":"https://search.dev.ndltd.org/etd/cape-town/oai:open.uct.ac.za:11427/3099","repository":{"repo_id":"cape-town","name":"University of Cape Town","base_url":"https://open.uct.ac.za/oai/request"},"display":{"title":"Pharmacogenomic profiling and clarification of the role of the mismatch repair genes in response to the chemotherapeutic agent 5-Fluorouracil in a South African colorectal cancer cohort","abstract":"To date, surgery is the mainstay treatment for HNPCC. Adjuvant chemotherapy and radiotherapy are often used to reduce systemic and locoregional recurrence, respectively, after curative surgical resection. The main chemotherapeutic agent is 5-Fluoroucacil (5-FU). Studies have attempted to elucidate whether the MMR status of a colorectal cancer (CRC) cohort will define a response to 5-FU therapy. However, no difference in long term response or survival after 5-FU treatment between patients with MMR-proficient and MMR-deficient tomours were detected.","abstract_html":"To date, surgery is the mainstay treatment for HNPCC. Adjuvant chemotherapy and radiotherapy are often used to reduce systemic and locoregional recurrence, respectively, after curative surgical resection. The main chemotherapeutic agent is 5-Fluoroucacil (5-FU). Studies have attempted to elucidate whether the MMR status of a colorectal cancer (CRC) cohort will define a response to 5-FU therapy. However, no difference in long term response or survival after 5-FU treatment between patients with MMR-proficient and MMR-deficient tomours were detected.","abstract_has_math":false,"creators":["Meyer, Jacqueline"],"institution":"Division of Human Genetics","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":["Ramesar, Raj"],"committee_chairs":[],"committee_members":[],"year":2009,"date_issued":"2009","date_published":"2009","updated_at":"2026-07-22T22:23:13Z","subjects":[],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/11427/3099","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Ramesar, Raj"]},{"key":"dc:creator","label":"Author","values":["Meyer, Jacqueline"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2014-07-28T14:52:31Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2014-07-28T14:52:31Z"]},{"key":"dc:date.issued","label":"Date","values":["2009"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["Division of Human Genetics"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Cape Town"]},{"key":"dc:type","label":"Dc Type","values":["Master Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["Masters"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["MSc"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/11427/3099"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Includes abstract.","Includes bibliographical references (leaves 106-120)."]},{"key":"dc:description.abstract","label":"Abstract","values":["To date, surgery is the mainstay treatment for HNPCC. Adjuvant chemotherapy and radiotherapy are often used to reduce systemic and locoregional recurrence, respectively, after curative surgical resection. The main chemotherapeutic agent is 5-Fluoroucacil (5-FU). Studies have attempted to elucidate whether the MMR status of a colorectal cancer (CRC) cohort will define a response to 5-FU therapy. However, no difference in long term response or survival after 5-FU treatment between patients with MMR-proficient and MMR-deficient tomours were detected."]},{"key":"dc:title","label":"Title","values":["Pharmacogenomic profiling and clarification of the role of the mismatch repair genes in response to the chemotherapeutic agent 5-Fluorouracil in a South African colorectal cancer cohort"]}]}],"canonical_facts":{"dc:contributor.advisor":["Ramesar, Raj"],"dc:creator":["Meyer, Jacqueline"],"dc:date.accessioned":["2014-07-28T14:52:31Z"],"dc:date.available":["2014-07-28T14:52:31Z"],"dc:date.issued":["2009"],"dc:description":["Includes abstract.","Includes bibliographical references (leaves 106-120)."],"dc:description.abstract":["To date, surgery is the mainstay treatment for HNPCC. Adjuvant chemotherapy and radiotherapy are often used to reduce systemic and locoregional recurrence, respectively, after curative surgical resection. The main chemotherapeutic agent is 5-Fluoroucacil (5-FU). Studies have attempted to elucidate whether the MMR status of a colorectal cancer (CRC) cohort will define a response to 5-FU therapy. However, no difference in long term response or survival after 5-FU treatment between patients with MMR-proficient and MMR-deficient tomours were detected."],"dc:identifier.uri":["http://hdl.handle.net/11427/3099"],"dc:language.iso":["eng"],"dc:publisher.department":["Division of Human Genetics"],"dc:publisher.institution":["University of Cape Town"],"dc:title":["Pharmacogenomic profiling and clarification of the role of the mismatch repair genes in response to the chemotherapeutic agent 5-Fluorouracil in a South African colorectal cancer cohort"],"dc:type":["Master Thesis"],"dc:type.qualificationlevel":["Masters"],"dc:type.qualificationname":["MSc"]},"updated_at":"2026-07-22T22:23:13Z"}